文献速递乳腺癌放疗放疗物理与技术

霍奇金淋巴瘤放疗后乳腺癌发生部位剂量回顾性估算方法

Retrospective methods to estimate radiation dose at the site of breast cancer development after Hodgkin lymphoma radiotherapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2017-10-24

该研究针对174例荷兰和170例英国霍奇金淋巴瘤治疗后发生乳腺癌的女性患者,将乳腺癌三维位置映射到CT体模上,用治疗计划系统计算46种放疗野设置下的剂量分布,估算乳腺癌中心点剂量中位数为29.75 Gy(IQR 5.8-37.2),约为处方剂量的75%,观察者间一致性优秀(ICC 0.89),方法间一致性接近良好(ICC 0.59)。

要点

  • 乳腺癌中心点估算剂量中位数为29.75 Gy,约为处方放疗剂量的75%。
  • 观察者间变异ICC为0.89(95% CI: 0.74-0.95),一致性优秀。
  • 方法间绝对一致性ICC为0.59(95% CI: 0.37-0.75),接近良好。

核心结论

  • 乳腺癌发生部位剂量估算在不同方法间显示良好相关性,但回顾性估算始终存在一定不确定性需加以考虑。

研究设计与样本

  • 回顾性剂量估算研究,纳入174例荷兰和170例英国霍奇金淋巴瘤治疗后发生乳腺癌的女性患者。
  • 将乳腺癌三维位置转移到CT基仿人体体模上,用放疗治疗计划系统计算研究人群使用的46种不同放疗野设置的剂量分布。
  • 基于肿瘤位置和治疗计划等剂量线确定乳腺癌中心点估算剂量及反映剂量不确定性的边界,并评估观察者间变异,对47例患者与先前应用的剂量学方法进行比较。

主要发现

  • 乳腺癌位置中心点估算中位点剂量为29.75 Gy(IQR 5.8-37.2),约为处方放疗剂量的75%。
  • 中位剂量不确定范围为5.97 Gy。
  • 观察者间变异优秀,ICC为0.89(95% CI: 0.74-0.95)。
  • 方法间变异的绝对一致性组内相关系数(ICC)为0.59(95% CI: 0.37-0.75),表明接近良好的一致性。
  • 观察者间或方法间剂量估算无系统性差异。

临床怎么用

  • 该回顾性剂量估算方法可用于评估霍奇金淋巴瘤放疗后乳腺癌发生部位的剂量-反应关系,辅助临床决策。
  • 观察者间一致性优秀且方法间无系统差异,提示该方法在多观察者和不同方法间具有可重复性。
  • 因回顾性估算存在不确定性(中位不确定范围5.97 Gy),临床应用时需考虑剂量估算的误差范围。

局限性

  • 估算的回顾性性质意味着始终存在一定不确定性需加以考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An increased risk of breast cancer following radiotherapy for Hodgkin lymphoma (HL) has now been robustly established. In order to estimate the dose-response relationship more accurately, and to aid clinical decision making, a retrospective estimation of the radiation dose delivered to the site of the subsequent breast cancer is required. METHODS: For 174 Dutch and 170 UK female patients with breast cancer following HL treatment, the 3-dimensional position of the breast cancer in the affected breast was determined and transferred onto a CT-based anthropomorphic phantom. Using a radiotherapy treatment planning system the dose distribution on the CT-based phantom was calculated for the 46 different radiation treatment field set-ups used in the study population. The estimated dose at the centre of the breast cancer, and a margin to reflect dose uncertainty were determined on the basis of the location of the tumour and the isodose lines from the treatment planning. We assessed inter-observer variation and for 47 patients we compared the results with a previously applied dosimetry method. RESULTS: The estimated median point dose at the centre of the breast cancer location was 29.75 Gy (IQR 5.8-37.2), or about 75% of the prescribed radiotherapy dose. The median dose uncertainty range was 5.97 Gy. We observed an excellent inter-observer variation (ICC 0.89 (95% CI: 0.74-0.95)). The absolute agreement intra-class correlation coefficient (ICC) for inter-method variation was 0.59 (95% CI: 0.37-0.75), indicating (nearly) good agreement. There were no systematic differences in the dose estimates between observers or methods. CONCLUSION: Estimates of the dose at the point of a subsequent breast cancer show good correlation between methods, but the retrospective nature of the estimates means that there is always some uncertainty to be accounted for.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Russell NS, Krul IM, van Eggermond AM, et al. Retrospective methods to estimate radiation dose at the site of breast cancer development after Hodgkin lymphoma radiotherapy. Clin Transl Radiat Oncol. 2017. PMID: 29594225. doi:10.1016/j.ctro.2017.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。